Artificial Intelligence (AI)-based Identification of Biomarkers in Urothelial Tumor Survivors: Integrating Multiomics

Our primary goal is to identify novel biomarkers (e.g. markers of tumor growth, cell cycle progression, senescence, autophagy, and the tumor microenvironment) by multiomics technologies that predict prognosis in long-term survivors, enhancing patient management and individualized treatment strategies. Of particular interest is the analysis beyond the tumor characteristics, focusing on the cellular neighborhood and cell-to-cell interactions. Given the high incidence and complexity of MIBC, ongoing research is essential for integrating emerging therapies and improving patients' quality of life.